HMGB1 and Miyoshi myopathy: Given that MM patients often exhibit persistently high HMGB1 levels despite reduced asbestos exposure, disrupting this loop may provide a dual benefit by simultaneously lowering both HMGB1 and TLR4 expression and activity.